Editas Medicine, Inc.
EDIT
$1.33
-$0.21-13.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -49.03% | -98.86% | -82.23% | -88.48% | 818.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -49.03% | -98.86% | -82.23% | -88.48% | 818.74% |
| Cost of Revenue | -30.11% | 17.59% | -15.84% | 29.05% | 33.77% |
| Gross Profit | -89.41% | -35.26% | -545.30% | -70.47% | 79.09% |
| SG&A Expenses | 13.14% | 20.69% | 5.84% | -15.95% | -19.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.67% | 18.43% | 54.14% | 12.03% | 20.05% |
| Operating Income | -43.40% | -30.91% | -63.07% | -31.46% | 62.23% |
| Income Before Tax | -140.52% | -38.03% | -67.80% | -26.34% | 68.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -140.52% | -38.03% | -67.80% | -26.34% | 68.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.52% | -38.03% | -67.80% | -26.34% | 68.93% |
| EBIT | -43.40% | -30.91% | -63.07% | -31.46% | 62.23% |
| EBITDA | -46.60% | -31.69% | -65.63% | -32.71% | 63.64% |
| EPS Basic | -137.88% | -36.63% | -45.51% | -6.28% | 73.84% |
| Normalized Basic EPS | -89.93% | -36.62% | -45.52% | -6.25% | 76.06% |
| EPS Diluted | -137.88% | -36.63% | -45.51% | -6.28% | 73.84% |
| Normalized Diluted EPS | -89.93% | -36.62% | -45.52% | -6.25% | 76.06% |
| Average Basic Shares Outstanding | 1.11% | 1.03% | 15.32% | 18.88% | 18.78% |
| Average Diluted Shares Outstanding | 1.11% | 1.03% | 15.32% | 18.88% | 18.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |